Genomic and functional characterization of a novel halophilic bacteriophage targeting carbapenem-resistant Klebsiella pneumoniae

May 2026 in “ PLoS ONE ”

Sahar Abed, Masoumeh Beig, Sepideh Soltani, Mohadeseh Pahlevani, Peter Speck, Morvarid Shafiei, Abdolrazagh Hashemi Shahraki, Abozar Ghorbani

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on journals.plos.org →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Development of Phage-Containing Hydrogel for Treating Enterococcus Faecalis-Infected Wounds

11 citations , October 2024 in “PLoS ONE”

Phage-containing hydrogels effectively heal wounds infected with Enterococcus faecalis.

Related Community Posts Join

6 / 1000+ results

community Link to the conference for Kintor Pyrilutamide

in Research/Science 41 upvotes 4 years ago

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

community Anagenic is trying to compound Gt20029

in Treatment 56 upvotes 3 years ago

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 4 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community Kintor Phase 2 Results released KX-826 (pyrilutamide)

in Research/Science 445 upvotes 3 years ago

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

community The story of RU58841/PSK3841

in Research/Science 1 year ago

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy

in Research/Science 10 upvotes 5 years ago

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.